Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MSN Facing 2026 Wait On US Cabozantinib – Or Will It Be 2032?

May 2022 Trial Is Mixed For MSN; Second Trial Set For October 2023

Executive Summary

In a closely-watched case, the first of two planned in less than 18 months, MSN Laboratories scooped a mixed verdict from a US district court regarding its proposed generic version of Exelixis’ Cabometyx (cabozantinib) tyrosine kinase inhibitor.

You may also be interested in...

Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data

Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.

Lannett Eyes Another $11M In Savings With R&D Sea Change, Job Cuts

Lannett unveiled another round of cost-saving initiatives alongside its financial Q2 earnings, including plans for a radical change for its R&D development.

Is There A Biosimilar Future For A Smaller Target Like Synagis?

With something of a revolution in the RSV space on the horizon, Generics Bulletin looks at the potential for biosimilar competition in developed markets to AstraZeneca/SOBI’s existing benchmark option, the 25-year-old prophylactic Synagis (palivizumab).


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts